Wiki source code of Neurodiagnoses
                  Last modified by manuelmenendez on 2025/03/03 22:46
              
      Hide last authors
| author | version | line-number | content | 
|---|---|---|---|
|                              | 
      1.1 | 1 | (% class="jumbotron" %) | 
| 2 | ((( | ||
| 3 | (% class="container" %) | ||
| 4 | ((( | ||
|        | 
      40.1 | 5 | = //A new tridimensional diagnostic framework for complex CNS diseases// = | 
|        | 
      1.1 | 6 | |
|        | 
      40.1 | 7 | This project is focused on developing a novel nosological and diagnostic framework for complex CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. | 
|        | 
      6.1 | 8 | We aim to create a structured, interpretable, and scalable diagnostic tool. | 
|        | 
      1.1 | 9 | ))) | 
| 10 | ))) | ||
| 11 | |||
| 12 | (% class="row" %) | ||
| 13 | ((( | ||
| 14 | (% class="col-xs-12 col-sm-8" %) | ||
| 15 | ((( | ||
|        | 
      6.1 | 16 | = What is this about and what can I find here? = | 
|        | 
      1.1 | 17 | |
|        | 
      27.1 | 18 | = **Overview** = | 
|        | 
      6.1 | 19 | |
|        | 
      47.1 | 20 | The classification and diagnosis of central nervous system (CNS) diseases have long been constrained by traditional, phenotype-based approaches that often fail to capture the complex interplay of pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes. | 
|        | 
      28.1 | 21 | |
|        | 
      47.1 | 22 | **Neurodiagnoses** redefines this landscape by integrating advanced AI with multi-modal data—including genetics, neuroimaging, biomarkers, and digital health records—to create a more precise, scalable, and data-driven diagnostic system. | 
|        | 
      29.1 | 23 | |
|        | 
      47.1 | 24 | Additionally, **Neurodiagnoses is now expanding into disease prediction and biomarker estimation**, integrating state-of-the-art machine learning models to enhance precision diagnostics and disease progression forecasting. | 
|        | 
      33.1 | 25 | |
|        | 
      43.1 | 26 | On this page, you will find: | 
|        | 
      6.1 | 27 | |
|        | 
      43.1 | 28 | * Detailed descriptions of both the clinical diagnostic tools and the research framework. | 
| 29 | * Access to our AI models, data processing pipelines, and digital twin simulations. | ||
| 30 | * Collaborative resources for researchers, clinicians, and AI developers. | ||
| 31 | * Guidelines and instructions on how to contribute to and expand the project. | ||
|        | 
      6.1 | 32 | |
|        | 
      41.1 | 33 | == **The role of AI-powered annotation** == | 
|        | 
      33.1 | 34 | |
|        | 
      36.1 | 35 | To enhance standardization, interpretability, and clinical application, the framework integrates an AI-powered annotation system, which: | 
|        | 
      33.1 | 36 | |
|        | 
      47.1 | 37 | * Assigns structured metadata tags to diagnostic features. | 
|        | 
      36.1 | 38 | * Provides real-time contextual explanations for AI-based classifications. | 
| 39 | * Tracks longitudinal disease progression using timestamped AI annotations. | ||
| 40 | * Improves AI model transparency through interpretability tools (e.g., SHAP analysis). | ||
| 41 | * Facilitates decision-making for clinicians by linking annotations to standardized biomedical ontologies (SNOMED, HPO). | ||
|        | 
      33.1 | 42 | |
|        | 
      47.1 | 43 | Neurodiagnoses provides **two complementary AI-driven diagnostic approaches**: | 
|        | 
      37.1 | 44 | |
|        | 
      47.1 | 45 | 1. **Probabilistic Diagnosis** | 
| 46 | * AI assigns probability scores to multiple possible diagnoses based on biomarker, imaging, and clinical data. | ||
| 47 | * Useful for differential diagnosis and treatment decision-making. | ||
|        | 
      37.1 | 48 | |
|        | 
      47.1 | 49 | 2. **Tridimensional Diagnosis** | 
| 50 | * Diagnoses are structured based on: | ||
| 51 | - **(1) Etiology** (genetic, autoimmune, metabolic, infectious). | ||
| 52 | - **(2) Molecular Biomarkers** (amyloid-beta, tau, inflammatory markers, EEG patterns). | ||
| 53 | - **(3) Neuroanatomoclinical Correlations** (brain atrophy, connectivity alterations). | ||
| 54 | * This approach enables precise disease subtyping and biologically meaningful classification, particularly useful for tracking progression over time. | ||
|        | 
      37.1 | 55 | |
|        | 
      47.1 | 56 | Both systems will be offered for every patient case, allowing clinicians to compare AI-generated probabilistic diagnosis with a structured tridimensional classification. | 
|        | 
      37.1 | 57 | |
|        | 
      47.1 | 58 | == **Disease Prediction and Biomarker Estimation** == | 
|        | 
      37.1 | 59 | |
|        | 
      47.1 | 60 | Neurodiagnoses is also implementing **biomarker prediction and disease progression modeling**, using advanced machine learning techniques: | 
|        | 
      37.1 | 61 | |
|        | 
      47.1 | 62 | * **Biomarker Prediction:** | 
| 63 | - Estimation of fluid-based and neuroimaging biomarkers without invasive testing. | ||
| 64 | - Multi-modal machine learning models for predicting molecular and clinical markers. | ||
|        | 
      37.1 | 65 | |
|        | 
      47.1 | 66 | * **Disease Progression Modeling:** | 
| 67 | - AI-driven forecasts for neurodegenerative disease evolution. | ||
| 68 | - Probabilistic disease conversion models (e.g., MCI to AD, Parkinson's prodromal phases). | ||
| 69 | - Survival models and risk stratification for precision medicine applications. | ||
| 70 | |||
|        | 
      23.1 | 71 | == **The case of neurodegenerative diseases** == | 
|        | 
      6.1 | 72 | |
|        | 
      23.1 | 73 | There have been described these 3 diagnostic axes: | 
| 74 | |||
|        | 
      25.1 | 75 | [[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] | 
| 76 | |||
|        | 
      6.1 | 77 | * ((( | 
| 78 | **Axis 1: Etiology** | ||
| 79 | * //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. | ||
| 80 | * //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. | ||
|        | 
      23.1 | 81 | * //Tests//: Genetic testing, lifestyle, and cardiovascular screening. | 
|        | 
      6.1 | 82 | ))) | 
| 83 | * ((( | ||
| 84 | **Axis 2: Molecular Markers** | ||
| 85 | * //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. | ||
| 86 | * //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. | ||
| 87 | * //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). | ||
| 88 | ))) | ||
| 89 | * ((( | ||
| 90 | **Axis 3: Neuroanatomoclinical** | ||
| 91 | * //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. | ||
| 92 | * //Examples//: Hippocampal atrophy correlating with memory deficits. | ||
| 93 | * //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. | ||
| 94 | ))) | ||
| 95 | |||
|        | 
      9.1 | 96 | == **Applications** == | 
|        | 
      6.1 | 97 | |
| 98 | This system enhances: | ||
| 99 | |||
|        | 
      47.1 | 100 | * **Research**: By stratifying patients, reducing cohort heterogeneity in clinical trials. | 
|        | 
      6.1 | 101 | * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. | 
| 102 | |||
|        | 
      10.1 | 103 | == How to Contribute == | 
|        | 
      4.4 | 104 | |
| 105 | * Access the `/docs` folder for guidelines. | ||
| 106 | * Use `/code` for the latest AI pipelines. | ||
| 107 | * Share feedback and ideas in the wiki discussion pages. | ||
|        | 
      46.1 | 108 | * Join our [[Community on EBRAINS>>https://community.ebrains.eu/_ideas/-OJHTZrpKrrrkx-u0djj/about]] | 
|        | 
      45.1 | 109 | * Join the [[Discussion Forum at GitHub>>https://github.com/Fundacion-de-Neurociencias/neurodiagnoses/discussions]] | 
|        | 
      5.1 | 110 | |
|        | 
      10.1 | 111 | == Key Objectives == | 
|        | 
      5.1 | 112 | |
| 113 | * Develop interpretable AI models for diagnosis and progression tracking. | ||
| 114 | * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. | ||
| 115 | * Foster collaboration among neuroscientists, AI researchers, and clinicians. | ||
|        | 
      42.1 | 116 | * Provide a dual diagnostic system: | 
|        | 
      47.1 | 117 | ** Probabilistic Diagnosis – AI assigns multiple traditional possible diagnoses with probability percentages. | 
| 118 | ** Tridimensional Diagnosis – AI structures diagnoses based on etiology, biomarkers, and neuroanatomical correlations. | ||
| 119 | * Implement disease prediction models for neurodegenerative conditions. | ||
| 120 | * Predict biomarkers from non-invasive data sources. | ||
|        | 
      31.1 | 121 | |
| 122 | == Who has access? == | ||
| 123 | |||
|        | 
      43.1 | 124 | We welcome contributions from the global community. Join us as we transform CNS diagnostics and drive precision medicine forward through a collaborative, open-source approach. Let’s build the future of neurological diagnostics together! | 
|        | 
      1.1 | 125 | ))) | 
| 126 | |||
| 127 | (% class="col-xs-12 col-sm-4" %) | ||
| 128 | ((( | ||
| 129 | {{box title="**Contents**"}} | ||
| 130 | {{toc/}} | ||
| 131 | {{/box}} | ||
| 132 | |||
|        | 
      10.1 | 133 | == Main contents == | 
|        | 
      4.4 | 134 | |
|        | 
      5.1 | 135 | * `/docs`: Documentation and contribution guidelines. | 
| 136 | * `/code`: Machine learning pipelines and scripts. | ||
| 137 | * `/data`: Sample datasets for testing. | ||
| 138 | * `/outputs`: Generated models, visualizations, and reports. | ||
|        | 
      21.1 | 139 | * [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] | 
|        | 
      35.1 | 140 | * [[Notebooks>>Notebooks]] | 
|        | 
      21.1 | 141 | * [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] | 
|        | 
      22.1 | 142 | * [[to-do-list>>to-do-list]] | 
|        | 
      1.1 | 143 | ))) | 
| 144 | ))) | ||
|        | 
      47.1 | 145 |